EU gives nod to Stentys' DES
The European Union has granted a CE Mark to Stentys for its drug-eluting stent (DES) to treat acute coronary syndrome (ACS).

According to the Princeton, N.J.-based company, the self-expanding stent alleviates malapposition by being applied to the internal wall of the vessel for apposition after an acute MI procedure even during thrombus resolutions or vessel spasm relief.

With the new mark of approval, Stentys will be able to market its DES across Europe.